Last reviewed · How we verify

autogenous dentin graft

Bahçeşehir University · FDA-approved active Biologic ✓ Verified May 2026 Quality 5/100

autogenous dentin graft is a Biologic drug developed by Bahçeşehir University. It is currently FDA-approved.

Autogenous dentin graft is a treatment used for conditions such as augmentation, socket preservation, and stage 3 periodontitis, typically involving the use of a tooth block or autogenous bone block. The exact mechanism of autogenous dentin graft is not specified in the provided information, but it is not related to oligonucleotides or personalized cancer vaccines.

At a glance

Generic nameautogenous dentin graft
SponsorBahçeşehir University
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about autogenous dentin graft

What is autogenous dentin graft?

autogenous dentin graft is a Biologic drug developed by Bahçeşehir University.

Who makes autogenous dentin graft?

autogenous dentin graft is developed and marketed by Bahçeşehir University (see full Bahçeşehir University pipeline at /company/bah-e-ehir-university).

What development phase is autogenous dentin graft in?

autogenous dentin graft is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing